Aspen Neuroscience, Bambusa Therapeutics Each Target Up to $159.5M in IPOs Amid Biotech Listing Trend

Aspen Neuroscience and Bambusa Therapeutics on Monday launched their U.S. initial public offering roadshows, continuing a steady stream of biotech listings in an otherwise quiet market. Both clinical-stage drug developers are seeking to capitalize on investor demand for companies with specific clinical catalysts.

Offering Details

Both companies are marketing their offerings with identical terms, according to filings. A successful IPO at the top of the range would provide significant funding for their respective clinical trials.

• Shares Offered: Each company plans to sell 9.38 million shares.
• Price Range: The shares are being marketed at a price between $15 and $17 apiece.
• Potential Proceeds: At the high end of the range, each IPO could raise up to $159.5 million.

Aspen Neuroscience will trade on the Nasdaq under the ticker symbol "ASPE," while Bambusa Therapeutics will list under "BBTX."

Biotech Defies IPO Slowdown

The biotech sector has been a notable bright spot in a fall IPO window marked by market choppiness and rising borrowing costs, which have deterred issuers from other industries. According to a Reuters report, more than half a dozen biotech firms have gone public in New York since September.

Ad

Lukas Muehlbauer, an associate at IPOX, told Reuters that the sector's appeal lies in its potential for returns based on clinical developments, which can be independent of the broader economic climate. "Biotech offers investors opportunities where clinical catalysts can drive returns even when the broader economic outlook is uncertain," Muehlbauer said.

However, Muehlbauer also noted that investor appetite remains selective, with higher financing costs presenting a challenge for companies that are years away from generating revenue.

Company Pipelines

Aspen Neuroscience, based in San Diego, California, is focused on developing therapies for neurodegenerative conditions. Its lead product candidate, sasineprocel, is in an early-to-mid-stage clinical trial for treating Parkinson’s disease.

Bambusa Therapeutics, based in Boston, Massachusetts, develops drugs for immunological and inflammatory disorders. Its primary candidate, BBT001, is in early-stage development to treat a form of dermatitis and other inflammatory skin diseases.